Skip to content

Study · Randomized controlled trial · n = 151 · 1994

3 results

The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy.

Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G

Endoscopy1 Nov 1994Cited by 51 (Europe PMC)

PMID7536155 (opens in a new tab)DOI10.1055/s-2007-1009081 (opens in a new tab)PepBankPUB-07536155
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After sphincterotomy, octreotide reduced the serum amylase increase versus placebo, with statistical significance only at 48 hours.

    In plain wordsAfter sphincterotomy, octreotide reduced the amylase increase versus placebo, but the difference was significant only at 48 hours.

    Peptide
    Octreotide
    Outcome
    DecreaseSerum amylase increase
    Study

    n = 151

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.1 mg at 120 and 30 min before EST and four hours after · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After EST, the increase in the mean serum amylase was greater in the control group, but the difference was statistically significant only at the 48-hour measurement.
    4 context sentences
    Summary · context
    Serum amylases (normal range 20-220 IU/l) were measured before premedication and 4, 24, and 48 hours after the end of endoscopy.
    Summary · context
    We evaluated the potential of octreotide, a long-acting somatostatin analogue, to prevent these complications in patients who underwent EST for choledocholithiasis.
    Summary · context
    151 patients were randomly allocated to two groups (A and B).
    Summary · context
    Group A was given 0.1 mg of octreotide subcutaneously 120 and 30 min before EST and four hours after; group B was given a placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After sphincterotomy, acute pancreatitis occurred in five patients in each of the octreotide and placebo groups.

    In plain wordsAfter sphincterotomy, five patients in each octreotide and placebo group developed acute pancreatitis.

    Peptide
    Octreotide
    Outcome
    No significant changeAcute pancreatitis incidence
    Study

    n = 151

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.1 mg at 120 and 30 min before EST and four hours after · subcutaneousAs given in this study (human).

    Measurements

    Acute pancreatitis cases
    5 cases
    octreotide group
    Acute pancreatitis cases
    5 cases
    placebo group

    Source sentences

    Summary
    There were five cases of acute pancreatitis in each group, with a trend (but not statistically significant) toward less severe pancreatitis in the treated group.
    3 context sentences
    Summary · context
    We evaluated the potential of octreotide, a long-acting somatostatin analogue, to prevent these complications in patients who underwent EST for choledocholithiasis.
    Summary · context
    151 patients were randomly allocated to two groups (A and B).
    Summary · context
    Group A was given 0.1 mg of octreotide subcutaneously 120 and 30 min before EST and four hours after; group B was given a placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    After sphincterotomy, octreotide showed a non-significant trend toward less severe pancreatitis than placebo.

    In plain wordsAfter sphincterotomy, pancreatitis tended to be less severe with octreotide than placebo, without statistical significance.

    Peptide
    Octreotide
    Outcome
    DecreaseAcute pancreatitis severity
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.1 mg at 120 and 30 min before EST and four hours after · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were five cases of acute pancreatitis in each group, with a trend (but not statistically significant) toward less severe pancreatitis in the treated group.
    3 context sentences
    Summary · context
    We evaluated the potential of octreotide, a long-acting somatostatin analogue, to prevent these complications in patients who underwent EST for choledocholithiasis.
    Summary · context
    151 patients were randomly allocated to two groups (A and B).
    Summary · context
    Group A was given 0.1 mg of octreotide subcutaneously 120 and 30 min before EST and four hours after; group B was given a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.